Skip to main content

Research Repository

Advanced Search

Current and emerging investigational venetoclax-based therapies in chronic lymphocytic leukemia

Molica, Stefano; Allsup, David; Gianfelici, Valentina; Levato, Luciano; Aiello, Vincenzo; Bailey, James; Polliack, Aaron

Authors

Stefano Molica

Profile Image

Dr David Allsup D.J.Allsup@hull.ac.uk
Senior Lecturer in Haematology and Honorary Consultant

Valentina Gianfelici

Luciano Levato

Vincenzo Aiello

James Bailey

Aaron Polliack



Abstract

Introduction: Venetoclax has emerged as a breakthrough treatment which has revolutionized the therapeutic paradigm of chronic lymphocytic leukemia (CLL). This is primarily attributed to the efficacy of venetoclax as a time-limited, chemo-free, therapy in a field dominated by targeted agents given on a continuous schedule. Furthermore, compelling clinical data support the use of venetoclax in combination with other targeted agents in the hope of preventing drug resistance due to the emergence of acquired mutations. Areas covered: This paper provides an overview of clinical results of newly approved or investigational venetoclax-based therapies for CLL. In view of current and potential roles in CLL care, the strengths and disadvantages of venetoclax-combinations are discussed. The MEDLINE database, ClinicalTrials.gov and conference proceedings were all reviewed to select the relevant literature. Expert opinion: While the advent of venetoclax-based combinations has significantly expanded the therapeutic options for patients with CLL, further research with longer follow-up is required to address remaining open questions such as (I) the role of venetoclax as fixed duration therapy(II) timing and threshold of minimal residual disease (MRD) assessment for therapy discontinuation, (III) the efficacy of novel triplet combinations with venetoclax as backbone therapy, (IV) indications for the re-initiation of therapy with venetoclax.

Citation

Molica, S., Allsup, D., Gianfelici, V., Levato, L., Aiello, V., Bailey, J., & Polliack, A. (in press). Current and emerging investigational venetoclax-based therapies in chronic lymphocytic leukemia. Expert Opinion on Investigational Drugs, https://doi.org/10.1080/13543784.2021.1924669

Journal Article Type Article
Acceptance Date Apr 26, 2021
Online Publication Date Apr 30, 2021
Deposit Date May 6, 2021
Publicly Available Date May 1, 2022
Journal Expert Opinion on Investigational Drugs
Print ISSN 1354-3784
Electronic ISSN 1744-7658
Publisher Taylor and Francis
Peer Reviewed Peer Reviewed
DOI https://doi.org/10.1080/13543784.2021.1924669
Keywords CLL; Chronic lymphocytic leukemia; Venetoclax; Combination therapy; Venetoclax-based therapies; Minimal residual disease; MRD
Public URL https://hull-repository.worktribe.com/output/3763459

Files






You might also like



Downloadable Citations